DESTINY-Breast04 Study Discussion with Dr. Shanu Modi

from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers

Discussing the DESTINY-Breast04 study which resulted in a paradigm shift, with the introduction of low HER2 positive breast cancer, and further approval of Trastuzumab Deruxtecan (T-DXd). In discussion with the lead author, Dr. Shanu Modi - Professor of Medicine at Memorial Sloan Kettering Cancer Center. Website: http://www.oncbrothers.com/  Twitter: https://twitter.com/oncbrothers  Contact us at [email protected]

Episode metadata supplied by the publisher feed · Published Dec 30, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

DESTINY-Breast04 Study Discussion with Dr. Shanu Modi

0:00 20:02

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Brothers: Practice-Changing Cancer Discussions?

This episode is 20 minutes long.

When was this Oncology Brothers: Practice-Changing Cancer Discussions episode published?

This episode was published on December 30, 2022.

Can I download this Oncology Brothers: Practice-Changing Cancer Discussions episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!